Encompass Health Corp (EHC) Stock Price & Analysis
Encompass Health Corp (EHC) rose 1.65% to USD 112.89 as of July 25, 2026 at 03:02 UTC, according to Nexqual real-time market data.
EHC last closed at USD 111.06; the session ranged USD 112.3–116.06 on volume of 816,656 shares. Market capitalization is $11.20B, with a 52-week range of USD 92.77–127.99 (NYQ). Source: Nexqual, July 25, 2026 at 03:02 UTC.
Key Statistics (as of July 25, 2026 at 03:02 UTC)
| Price | USD 112.89 |
|---|---|
| Change | ▲ 1.65% (up) |
| Previous Close | USD 111.06 |
| Open | USD 115 |
| Day Range | USD 112.3 – 116.06 |
| 52-Week Range | USD 92.77 – 127.99 |
| Volume | 816,656 shares |
| Market Cap | $11.20B |
| Exchange | NYQ |
Technical Analysis (EHC)
Nexqual's technical model rates EHC "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:02 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.98 (neutral) |
| vs SMA50 | Above (USD 105.22) |
| MACD | 2.41 (positive) |
Analyst Ratings (EHC)
Wall Street analysts rate EHC "Strong Buy" based on 12 analysts, with a mean price target of USD 140.5 (range USD 125–152), per Nexqual as of July 25, 2026 at 03:02 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 140.5 |
| High Target | USD 152 |
| Low Target | USD 125 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (EHC)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 1.48 |
| Revenue Estimate | $1.57B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.6 vs est 1.49 ▲ beat |
| 2025-12-31 | USD 1.46 vs est 1.3 ▲ beat |
| 2025-09-30 | USD 1.23 vs est 1.19 ▲ beat |
| 2025-06-30 | USD 1.4 vs est 1.21 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Financials & Fundamentals (EHC)
| Total Revenue | $6.07B |
|---|---|
| Revenue Growth (YoY) | +9.00% |
| Gross Margin | +43.49% |
| Operating Margin | +19.01% |
| Profit Margin | +10.04% |
| ROE | +25.23% |
| Debt / Equity | 82.84 |
| Current Ratio | 1.17 |
| Total Cash | $110.50M |
| Total Debt | $2.79B |
| Free Cash Flow | $284.11M |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Financial Health Score (EHC)
Nexqual rates Encompass Health Corp's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:02 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 43%, operating 19% |
| Balance Sheet | Mixed — $111M cash vs $2.79B debt |
| Cash Flow | Mixed — FCF $284M, slim 4.8% margin |
| Efficiency | Strong — ROE 25%, ROA 9.7% |
Ownership (EHC)
| Insider Ownership | +1.07% |
|---|---|
| Institutional Ownership | +101.67% |
| Shares Outstanding | 99.20M |
| Float | 97.92M |
| Short % of Float | +3.52% |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Leadership (EHC)
Encompass Health Corp is led by Mark J. Tarr (age 63), CEO, President & Director, per Nexqual as of July 25, 2026 at 03:02 UTC.
| CEO, President & Director | Mark J. Tarr (age 63) |
|---|---|
| Executive VP & CFO | Douglas E. Coltharp (age 63) |
| Executive VP & COO | Patrick W. Tuer (age 40) |
| Senior Vice President of Investor Relations & Strategic Planning | Mark Miller |
Major Backers & Investors (EHC)
Notable institutional backers of Encompass Health Corp include T. Rowe Price, Price (T.Rowe) Associates Inc, Wellington Management, according to Nexqual as of July 25, 2026 at 03:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 5.83% |
| Price (T.Rowe) Associates Inc | 5.79% |
| Wellington Management | 3.88% |
| Invesco | 3.41% |
| Alliancebernstein L.P. | 2.64% |
| Fuller & Thaler Asset Management Inc. | 2.25% |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 2.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.2% |
| BlackRock | 14.3% |
| State Street | 3.17% |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
From Encompass Health Corp's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We will continue to develop and implement post-acute solutions that allow us to apply our clinical expertise, large post-acute datasets, electronic medical record technologies, and strategic partnerships to drive improved patient outcomes and lower the cost of care across the entire post-acute episode.
- We believe our consistent and disciplined operating model allows us to be nimble and responsive to change as we have shown following a number of significant changes to our Medicare payment system. • Strategic Relationships .
- The post-acute innovation tools we have developed, and will continue to develop, support our strategic relationship initiatives by enhancing the effective and efficient management of patients across multiple post-acute care settings and facilitating high-quality patient care, improved care coordination, and network provider performance and cost management.
- We have extensive clinical experience from which we have developed standardized best practices and protocols.
Partnerships
- For de novo hospitals, we utilize a centralized and repeatable talent attraction and hiring process, including coordinated marketing across multiple digital media channels and close collaboration with hospital leadership teams.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSG | The Ensign Group, Inc. | USD 172.99 | ▲ 2.29% |
| CHE | Chemed Corp | USD 511.13 | ▲ 1.51% |
| ITGR | Integer Holdings Corporation | USD 98.62 | ▲ 2.13% |
| ACHC | Acadia Healthcare Company, Inc. | USD 34.51 | ▼ 0.78% |
| OPCH | Option Care Health, Inc. | USD 21.66 | ▲ 2.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:02 UTC. This page is informational and not investment advice.